Amarin Corp Plc (AMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The companys lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription capsule used as an adjunct to diet, for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia and high triglyceride levels or mixed dyslipidemia. The company is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy. Amarin markets the product in the US through wholesalers and specialty pharmacy providers. The company has subsidiaries in Ireland, the US, Scotland and Israel. Amarin is headquartered at Dublin, Ireland.

Amarin Corp Plc (AMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Amarin and HLS Therapeutics Enter into Agreement 11
Amarin Enters into Development Agreement with Eddingpharm 12
Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13
Licensing Agreements 15
Amarin Enters into Licensing Agreement with Mochida Pharma 15
Equity Offering 16
Amarin Raises USD65 Million in Public Offering of American Depositary Shares 16
Amarin Files Registration Statement for Public Offering of ADS 17
Amarin Announces Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 18
Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 20
Amarin Completes Public Offering Of Shares For US$121.5 Million 21
Debt Offering 23
Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23
Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24
Amarin Corporation Completes Private Placement For US$100 Million 25
Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For US$150 Million 26
Acquisition 27
Teva Pharma Rumored To Acquire Amarin 27
Amarin Corp Plc - Key Competitors 28
Amarin Corp Plc - Key Employees 29
Amarin Corp Plc - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 01, 2018: Amarin reports third quarter 2018 financial results and provides update on operations 31
Aug 01, 2018: Amarin reports second quarter 2018 financial results and provides update on operations 35
May 02, 2018: Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations 38
Feb 27, 2018: Amarin Reports Announces Fourth Quarter and Full Year 2017 Financial Results 40
Nov 01, 2017: Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations 45
Aug 02, 2017: Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations 47
May 03, 2017: Amarin reports lower Q1 net loss, re-affirms annual guidance 50
Feb 28, 2017: Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations 51
Jan 05, 2017: Amarin announces revenue forecast for 2017 54
Jan 05, 2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 56
Corporate Communications 58
Apr 23, 2018: Amarin Announces Promotes Aaron Berg To Chief Commercial Officer 58
Product News 59
06/12/2017: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides 59
05/18/2017: Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care 60
05/03/2017: Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations 61
03/16/2017: Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study 66
03/15/2017: Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology 67
01/05/2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 68
Clinical Trials 70
Sep 13, 2017: Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer 70
Aug 14, 2017: Amarin Provides Update on Vascepa 71
Other Significant Developments 73
Apr 04, 2018: Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa Promotion Initiatives 73
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List Of Tables


Amarin Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarin Corp Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amarin and HLS Therapeutics Enter into Agreement 11
Amarin Enters into Development Agreement with Eddingpharm 12
Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13
Amarin Enters into Licensing Agreement with Mochida Pharma 15
Amarin Raises USD65 Million in Public Offering of American Depositary Shares 16
Amarin Files Registration Statement for Public Offering of ADS 17
Amarin Announces Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 18
Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 20
Amarin Completes Public Offering Of Shares For US$121.5 Million 21
Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23
Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24
Amarin Corporation Completes Private Placement For US$100 Million 25
Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For US$150 Million 26
Teva Pharma Rumored To Acquire Amarin 27
Amarin Corp Plc, Key Competitors 28
Amarin Corp Plc, Key Employees 29
Amarin Corp Plc, Subsidiaries 30

List Of Figures


Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amarin Corp Plc (AMRN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The companys lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription

USD 250 View Report

Amarin Corporation PLC Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Amarin Corporation PLC Company Profile is a detailed strategic and analytical report on Amarin Corporation PLC. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Amarin Corp Plc (AMRN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The companys lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription

USD 250 View Report

Noble Corp PLC: Performance, Capabilities, Goals and Strategies in the Global Energy Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available